SAM #NCTR-2026-134171

FDA Seeks CNS Organoid Neuropharmacological Analysis Lab Services

The FDA's National Center for Toxicological Research (NCTR) is seeking laboratory services for CNS Organoid Neuropharmacological Analysis. - Government Buyer: - U.S. Food and Drug Administration (FDA) - National Center for Toxicological Research (NCTR) - Service Requested: - CNS Organoid Neuropharmacological Analysis Lab Services - Functional examination of neuromodulatory effects of a marketed small molecule drug on human CNS-3D brain organoids - Includes Ca2+ burst characterization, 5-HT5A receptor inhibitor co-treatment, viability assays, and transcriptomic (RNA sequencing) analysis - Study design involves 10 treatment groups with 32 organoids each, using 28Bio organoids - Deliverables: neuromodulatory effects data, receptor role data, viability data, transcriptomic data - OEMs and Vendors: - 28Bio (manufacturer of CNS-3D brain organoids) - Unique Requirements: - Use of human CNS-3D brain organoids from 28Bio - Comprehensive neuropharmacological and transcriptomic analysis - Specific focus on 5-HT5A receptor and Ca2+ burst activity - Place of Performance: - National Center for Toxicological Research, Jefferson, AR - FDA Office of Acquisition & Grant Services, Rockville, MD (contracting office) - Period of Performance: - One-time analysis contract, approximately 8 months duration

Description

See sources sought notice attached

View original listing